A new preprint out of the Stanford team working on this “gerozyme”.
Rebuilding Old Muscle: A Gerozyme Brake on Strength, and the Drug That Releases It
Aged muscle largely stops responding to the mechanical stress of resistance exercise, a problem called anabolic resistance. A Stanford team shows that a single enzyme that rises with age, 15-PGDH, is a major cause. This enzyme destroys prostaglandin E2 (PGE2), a local signaling lipid that muscle needs to grow. Blocking the enzyme with a small molecule (SW033291) in 28-month-old mice roughly tripled muscle PGE2, and when combined with an overload stimulus it restored muscle growth and increased contractile force by about 50 percent versus untreated controls. The drug worked by switching on an IGF1-driven communication circuit between muscle fibers and their neighboring cells. Blocking the IGF1 receptor erased the benefit, confirming the mechanism.
For anyone who has watched an older relative lose the ability to rise from a chair, the biology behind it is frustratingly stubborn. Younger people who lift weights for six weeks typically gain around 20 percent in strength. Older people doing the identical program often gain only about 5 percent. Muscle in later life simply stops listening to the signals that tell it to grow, a phenomenon researchers call anabolic resistance. Until now there has been no approved drug that fixes it.
A new preprint from Helen Blau’s laboratory at Stanford points to a specific molecular culprit and, more interestingly, a way around it. The team focused on prostaglandin E2, or PGE2, a short-lived signaling molecule that muscle releases when it is worked hard. PGE2 helps orchestrate repair and growth. The problem is an enzyme called 15-PGDH, which breaks PGE2 down. This enzyme accumulates with age across many tissues, and the group had previously flagged it as a hallmark of aging. In old muscle, the researchers found a double failure: the tissue makes less PGE2 to begin with, and it degrades what little it makes faster.
The experiment tested whether tipping that balance back could restore youthful growth. Using 28-month-old mice, roughly equivalent to humans in their late seventies to eighties, the team surgically overloaded a small calf muscle to mimic resistance training, then gave a daily injection of SW033291, a drug that blocks 15-PGDH. The intervention raised muscle PGE2 about threefold. On its own this did little. Combined with the overload stimulus, it produced roughly a 50 percent increase in muscle force compared with untreated overloaded muscle, along with larger fibers and more muscle stem cell activity. The authors describe the drug as an exercise amplifier rather than a replacement for exercise, because the two together produced far more than either alone.
Digging into the mechanism, the team sequenced about 200,000 individual cell nuclei and traced the signal. PGE2 prompted a specific class of fast-twitch fibers, the type IIb fibers, to pump out IGF1, a well known growth factor, which then signaled outward to stem cells, blood vessel cells, connective tissue, and immune cells to coordinate growth. When they blocked the IGF1 receptor, the drug stopped working. That closes the logical loop and identifies a druggable target. The caveats are substantial, and the work is a non-peer-reviewed preprint in mice, but the direction is promising.
Actionable Insights
The single practical message is old but reinforced here: keep doing resistance training into old age, because the drug in this study does nothing without a mechanical stimulus to amplify. Nutrition and loading remain the foundation.
On effect sizes, it helps to translate the numbers. In this study the drug plus overload raised muscle force by about 50 percent relative to overload alone. To picture the scale of the underlying aging problem, recall the human baseline the authors cite: young trainees gain roughly 20 percent strength over six weeks of lifting while older trainees gain about 5 percent, a fourfold gap. An intervention that closes a meaningful fraction of that gap would be clinically important. The drug also tripled the local level of PGE2, the growth signal, though a threefold change in a signaling molecule does not translate one to one into a threefold change in strength.
The honest take home is that this is a mouse study of a molecule you cannot yet buy. SW033291 is a research compound, not a supplement or approved medicine. There is no human dosing, no safety data in people, and no long term data here. The durable, evidence backed action remains progressive resistance training plus adequate protein, with this paper offering reason for optimism that a future pill could make that training work better in old age.
Context and Source
